Impact of Dietary Intervention on Serum Neurofilament Light Chain in Multiple Sclerosis

We examined sNfL levels of 40 participants at baseline and at the end of the study after 6 months using single molecule array assay. Results sNfL levels were investigated in 9 controls, 14 participants on CR, and 17 participants on AKD. Correlation analysis showed an association of sNfL with age and disease duration; an association was also found between sNfL and the Multiple Sclerosis Functional Composite. AKD significantly reduced sNfL levels at 6 months compared with the common diet group (p = 0.001). Discussion For clinical or study use, consider that AKD may incline sNfL levels independent of relapse activity up to 3 months after initiation. At 6 months, AKD, which complements current therapies, reduced sNfL levels, therefore suggesting potential neuroprotective effects in MS. A single cycle of seven-day fasting did not affect sNfL. AKD may be an addition to the armamentarium to help clinicians support patients with MS in a personalized manner with tailored diet strategies. Trial Registration Information Clinical trial registration number NCT01538355.
Source: Neurology Neuroimmunology and Neuroinflammation - Category: Neurology Authors: Tags: Clinical trials Randomized controlled (CONSORT agreement), Class II, Multiple sclerosis Article Source Type: research